Cambridge Financial Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.57M Buy
38,026
+860
+2% +$185K 3.33% 15
2026
Q1
$8.08M Buy
37,166
+355
+1% +$78.7K 3.02% 19
2025
Q4
$8.41M Sell
36,811
-917
-2% -$209K 3.21% 14
2025
Q3
$8.74M Buy
37,728
+10,431
+38% +$2.12M 3.39% 14
2025
Q2
$5.07M Sell
27,297
-10,706
-28% -$1.99M 2.56% 25
2025
Q1
$7.96M Sell
38,003
-300
-0.8% -$58.3K 3.46% 15
2024
Q4
$6.81M Buy
+38,303
New +$7.04M 2.81% 24
2024
Q2
$6.17M Buy
35,981
+2,255
+7% +$374K 2.77% 27
2024
Q1
$6.14M Buy
33,726
+2,040
+6% +$352K 2.72% 27
2023
Q4
$4.91M Sell
31,686
-2,634
-8% -$384K 2.46% 28
2023
Q3
$5.12M Buy
+34,320
New +$5.04M 2.79% 24
2022
Q4
$5.09M Sell
31,488
-2,085
-6% -$320K 2.84% 22
2022
Q3
$4.51M Buy
+33,573
New +$4.82M 2.71% 23
2015
Q4
Sell
-90,488
Closed -$4.92M 32
2015
Q3
$4.92M Sell
90,488
-4,470
-5% -$291K 2.94% 25
2015
Q2
$6.38M Buy
94,958
+779
+0.8% +$50.9K 3.4% 15
2015
Q1
$5.51M Buy
94,179
+84,294
+853% +$5.09M 2.73% 30
2014
Q4
$647K Buy
+9,885
New +$623K 3.15% 24

Other funds holding ABBV

Cambridge Financial Group's ABBV Position: Q2 2026 in Review

Cambridge Financial Group increased its AbbVie (ABBV) stake by 2.3% in Q2 2026, buying an estimated $185K and bringing the position to 38,026 shares worth $9.57M. The position accounts for 3.33% of the portfolio, ranked #15.

Cambridge Financial Group first reported a position in ABBV in Q4 2014 and has held it in 17 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Cambridge Financial Group held 38,026 shares of AbbVie worth $9.57M as of Q2 2026.
  • Cambridge Financial Group bought 860 AbbVie shares in Q2 2026, an estimated $185K.
  • AbbVie made up 3.33% of Cambridge Financial Group's portfolio in Q2 2026, its #15 holding.
  • Cambridge Financial Group first reported a position in AbbVie in Q4 2014 and has held it in 17 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cambridge Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.